

VLA15

Valneva's Lyme disease vaccine candidate - VLA15

Lyme disease is the most common vector-borne illness in the Northern Hemisphere. Valneva's candidate is the only vaccine in clinical development worldwide.

Valneva reported positive Phase 1 interim data for its Lyme disease vaccine candidate VLA15. The Company has successfully concluded the end of Phase 1 process for this candidate with the Food and Drug Administration (FDA) and has obtained alignment with regard to its Phase 2 strategy

Valneva is now finalizing details for Phase 2 and, subject to regulatory clearances, will enter Phase 2 clinical development at the end of 2018.

Valneva's vaccine candidate VLA15, under Fast Track Designation by the FDA, is a multivalent vaccine that targets the outer surface protein A (OspA) of *Borrelia*. Pre-clinical data showed that VLA15 has the potential for protection against the majority of *Borrelia* species pathogenic for humans